CG Oncology, Inc.
Clinical trials sponsored by CG Oncology, Inc., explained in plain language.
A biopharmaceutical company developing immunotherapies for bladder cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Bladder cancer breakthrough? virus therapy aims to stop recurrence Results expected Nov 2026 (estimated) May already have reported ↗ 🚀 Make-or-break
- Bladder cancer virus therapy shows promise in Mid-Stage trial Results expected Mar 2027 (estimated) May already have reported ↗
-
New Virus-Based therapy offered to bladder cancer patients who failed standard care
Disease control Expanded accessThis program provides early access to cretostimogene grenadenorepvec, a virus-based therapy, for patients with non-muscle invasive bladder cancer that has not responded to standard BCG treatment. Eligible participants have a specific type of bladder cancer (CIS with or without hi…
Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Bladder cancer virus therapy shows promise in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests a drug called cretostimogene grenadenorepvec in 325 people with high-risk non-muscle-invasive bladder cancer. The drug is a virus that is put directly into the bladder to attack cancer cells. The study looks at how well it works and how safe it is, includ…
Phase 2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC